logo
Share SHARE
FONT-SIZE Plus   Neg

Biogen Submits BLA For First Long-Lasting Factor VIII Therapy For Hemophilia A

Biogen Idec (BIIB) reported submitting a Biologics License Application or BLA to the U.S. Food and Drug Administration or FDA for the marketing approval of recombinant factor VIII Fc fusion protein or rFVIIIFc to treat hemophilia A. Recombinant FVIIIFc is the first hemophilia A product candidate in a new class of long-lasting clotting factor therapies being developed with the goal of reducing the burden of treatment for this condition.

If approved, rFVIIIFc would be the first major advance in hemophilia A treatment in more than two decades, according to the company. The regulatory submission was based on results from A-LONG, the largest registrational phase 3 trial in hemophilia A to date.

Biogen Idec added, "In our phase 3 study, patients treated with rFVIIIFc were able to inject rFVIIIFc once-weekly to twice-weekly, which creates the potential for those currently on prophylactic treatment to reduce injections by 50 to 100 per year. Moreover, patients currently treating bleeding episodes could potentially dose prophylactically once per week and maintain significant protection from bleeding with about the same total number of injections each year they use to treat bleeding episodes today."

On March 4, 2013 Biogen Idec announced the FDA accepted for review the company's BLA for its factor IX candidate, rFIXFc, for use in patients with hemophilia B.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Embark Veterinary Inc., a startup that makes dog DNA-testing kits for pet owners, vets and breeders, said it has raised $4.5 million in funding from investors and relocated its headquarters to Boston. The company intends to use the new funding to expand its canine genetic testing suite for pet owners, breeders, and veterinarians. Intel Corp. has completely shut down its wearables division about two weeks ago, CNBC reported, citing a person familiar with the matter. The company reportedly intends to focus on augmented reality. According to the CNBC report, Intel laid off about 80 percent of the team that made the Basis fitness watch in November 2016 and has now eliminated the division entirely. The Federal Trade Commission is investigating allegations that Amazon.com Inc. misled consumers about its pricing discounts, Reuters reported, citing a source close to the probe. The FTC probe is reportedly part of the agency's review of Amazon's proposed $13.4 billion deal to buy grocery chain Whole Foods Market Inc.
comments powered by Disqus
Follow RTT